NEOPLASMS BY SITE

This study tests capmatinib, a drug already approved for certain lung cancers, in adults with rare cancers that have specific MET gene changes. About 30 people will take part to see if the drug can shrink tumors or stop cancer from growing for at least 24 weeks. The goal is to fi…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. The trial involves about …

This study tests a new drug called pocenbrodib, given alone or with another drug (darolutamide), in people with metastatic castration-resistant prostate cancer (mCRPC) that has spread and stopped responding to standard hormone therapy. The goal is to find safe and effective doses…

This study tests atezolizumab, a drug already approved for some cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). About 30 adults and children with these genetic changes will receive the drug to see if their tum…

This study tests a new medicine, PF-08634404, combined with standard chemotherapy for people with colorectal cancer that has spread. About 800 adults who have not had prior treatment for metastatic disease will be randomly assigned to receive either the new drug or an approved dr…

This study tests a drug called entrectinib in people with rare cancers that have a specific gene change (ROS1 fusion). The drug is already approved for some lung cancers, and researchers want to see if it helps shrink tumors or stop them from growing in other cancer types. About …

This early-phase study tests whether a specially engineered virus called G207 is safe for children whose cerebellar brain tumors have come back or not responded to standard treatments. Up to 24 children aged 3 to 21 will receive the virus directly into the tumor, along with a low…

This study tests a drug called alectinib, already approved for some lung cancers, in people with rare cancers that have a specific genetic change called ALK. About 30 adults, teens, and children with ALK-positive cancers will receive alectinib to see if it shrinks tumors or stops…

This study tests whether giving two immunotherapy drugs (nivolumab with or without relatlimab) before surgery can eliminate bladder cancer completely, allowing some patients to avoid bladder removal. About 90 adults with stage II-IIIa bladder cancer that has spread into the muscl…